Cormark Has Bearish Estimate for Cresco Labs FY2025 Earnings

Cresco Labs Inc. (OTCMKTS:CRLBF - Free Report) - Equities researchers at Cormark cut their FY2025 EPS estimates for Cresco Labs in a research note issued to investors on Monday, March 17th. Cormark analyst J. Pytlak now anticipates that the company will post earnings of ($0.07) per share for the year, down from their prior forecast of $0.03. Cormark has a "Moderate Buy" rating on the stock. The consensus estimate for Cresco Labs' current full-year earnings is ($0.20) per share. Cormark also issued estimates for Cresco Labs' FY2026 earnings at $0.01 EPS.

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) last announced its quarterly earnings results on Friday, March 14th. The company reported ($0.01) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.01). Cresco Labs had a negative return on equity of 16.52% and a negative net margin of 9.15%. The firm had revenue of $176.00 million for the quarter, compared to analysts' expectations of $172.10 million.

Separately, Atb Cap Markets lowered Cresco Labs from a "strong-buy" rating to a "hold" rating in a research note on Monday, December 9th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $3.00.

Remove Ads

Cresco Labs Price Performance

OTCMKTS CRLBF traded down $0.00 during trading hours on Wednesday, reaching $0.73. 281,878 shares of the company's stock were exchanged, compared to its average volume of 608,755. The firm has a fifty day moving average of $0.86 and a 200-day moving average of $1.17. Cresco Labs has a one year low of $0.69 and a one year high of $2.60. The stock has a market cap of $356.34 million, a PE ratio of -3.65 and a beta of 1.79. The company has a current ratio of 1.97, a quick ratio of 1.39 and a debt-to-equity ratio of 1.80.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.